RBC Analysts See Caution in Big Pharma Stocks During Earnings Season
RBC Capital Markets analysts say investors appear increasingly cautious on big pharma stocks as third-quarter earnings unfold. They cite a negative reaction to Johnson & Johnson’s solid results last week as a sign of heightened vulnerability.